drugset
drugset / Trial / NCT02209844

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 44847 Powder in Healthy Male Subjects

NCT02209844 ↗

Phase 1 Completed 72 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 44847

Timeline

Start
2006-08
Primary completion
2007-01
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 44847 Unknown 2.5 mg Oral
Subject BI 44847 Unknown 1200 mg Oral

Indications

No indication recorded.